Estimating the lives that could be saved by expanded access to weight-loss drugs
Pandey A, Ye Y, Wells C, Singer B, Galvani A. Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2412872121. PMID: 39405358, PMCID: PMC11513960, DOI: 10.1073/pnas.2412872121.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Body mass index categoriesObesity prevalence dataGlucagon-like peptide-1 receptor agonistsHazard ratio of mortalityRatio of mortalityPublic health impactWeight loss drugsInsurance coverage issuesGastric inhibitory polypeptideHealthcare accessType 2 diabetesUnited StatesPublic health crisisObesity epidemicReceptor agonistsIndex categoriesHazard ratioPrevalence dataInhibitory polypeptidePeptide-1Health impactsNovel treatmentObesityHealth crisisEarly Release - Public Health Impact of Paxlovid as Treatment for COVID-19, United States - Volume 30, Number 2—February 2024 - Emerging Infectious Diseases journal - CDC
Bai Y, Du Z, Wang L, Lau E, Fung I, Holme P, Cowling B, Galvani A, Krug R, Meyers L. Early Release - Public Health Impact of Paxlovid as Treatment for COVID-19, United States - Volume 30, Number 2—February 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 262-269. PMID: 38181800, PMCID: PMC10826746, DOI: 10.3201/eid3002.230835.Peer-Reviewed Original Research